Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia

PHASE3CompletedINTERVENTIONAL
Enrollment

289

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

January 9, 2021

Study Completion Date

January 9, 2021

Conditions
Covid19
Interventions
DRUG

Tofacitinib 10 mg

Tofacitinib 10mg administered orally twice daily for 14 days or until hospital discharge

DRUG

Placebo

Tofacitinib-matching placebo administered orally twice daily for 14 days or until hospital discharge

Trial Locations (17)

Unknown

Centro de Pesquisa Clínica do Coração, Aracaju

Hospital Universitário São Francisco de Assis Na Providência de Deu, Bragança Paulista

Irmandade do Sr. Bom Jesus dos Passos da Santa Casa de Misericórdia de Bragança Paulista, Bragança Paulista

Hospital do Coração do Brasil, Brasília

Instituto de Pesquisa Clínica de Campinas, Campinas

Hospital Regional do Litoral Norte, Caraguatatuba

Unimed Fortaleza Sociedade Corporativa Médica LTD, Fortaleza

Hospital Regional Jorge Rossmann, Itanhaém

Hospital Bruno Born, Lajeado

Hospital São Vicente de Paulo, Passo Fundo

Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto

Hospital Regional de Registro, São José dos Campos

Hospital Regional de São José dos Campos, São José dos Campos

Beneficência Portuguesa, São Paulo

BP Mirante, São Paulo

Hospital Israelita Albert Einstein, São Paulo

Instituto do Coração, São Paulo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Hospital Israelita Albert Einstein

OTHER